Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Blood cell tracer pulled from market

Dec 20, 2005 | AP

A fairly new drug used to diagnose appendicitis was pulled off the market Monday after the government linked it to two deaths and life-threatening side effects.

The Food and Drug Administration ordered that NeutroSpec, an imaging agent, be taken off the market, and it warned health workers to stop using any of the drug still on their shelves.

Manufacturer Palatin Technologies said it would suspend sales and recall past shipments.

There is no risk to anyone who already received NeutroSpec, the FDA stressed. The allergic-type reactions occur within minutes of the drug's injection.

NeutroSpec carries a radioactive tracer to white blood cells and binds to them. When standard tests can't definitively diagnose appendicitis, doctors can use the drug and a radioactivity-spotting camera to tell whether white blood cells have clustered in the appendix, a sign of infection there.

In studies, NeutroSpec was administered to 523 patients with no serious side effects, the FDA said, leading the agency to approve the drug as an aid to diagnosing appendicitis.

But since sales began in September 2004, the FDA has learned of 17 patients who suffered life-threatening side effects, including heart failure, as soon as the drug was injected. Two died.

Most of the side effects occurred when NeutroSpec was used to diagnose infections other than appendicitis, the FDA said.

The agency is investigating the risk, and it plans to convene a meeting of its independent scientific advisers early next year to debate whether additional safety measures would allow Neutro-Spec to return to the market.

Related articles Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo